Eris Lifesciences financials

·Pharma & HealthChart ›
Latest results Q2 FY27 · Jul–Sep 2026
Revenue
₹892cr+12.6% on Q2 FY26
Net profit
₹187cr+39.2% on Q2 FY26
EBITDA margin
34.7%−1.7 pts on Q2 FY26
EPS
₹13.26+50.3% on Q2 FY26

Quarterly results

Every quarter ›
₹ croreQ2 FY27Q2 FY26Change
Revenue892792+12.6%
EBITDA309288+7.3%
EBITDA margin34.7%36.4%−1.7 pts
Profit before tax157172−9.0%
Net profit187134+39.2%
EPS₹13.26₹8.82+50.3%

Over time

Q2 FY27 · Jul–Sep 2026latest
Revenue₹892 crNet profit₹187 crNet margin21.0%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
16,279————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
23854.720594.286.0
−2.8−7.041763624.7
2,3102,3102,4782,735830
18,348————
3,3303,1292,8942,0091,685
—+8.1%+44.0%+19.2%—
1,1611,1201,017675537
34.9%35.8%35.2%33.6%31.9%
875841702492420
718648375397374
21.6%20.7%13.0%19.8%22.2%
₹51.09₹44.73₹25.40₹28.30₹27.59
—+76.1%−10.2%+2.6%—
—5381,065486292
—−297−155−129−841
241241910357−550
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ERIS₹1,175.40

Eris Lifesciences Ltd.

· Pharma & Health
₹ CrorePeersMANKINDAJANTPHARMTORNTPHARMEMCUREGRANULESCONCORDBIOINDGNCAPLIPOINTMcap ₹16,279 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————16,279.3
- Cash, Equiv & ST Investments86.094.2204.754.7238.1
+ Minority Interest24.7635.9417.4-7.0-2.8
+ Total Debt830.02,735.32,477.92,309.72,309.7
Enterprise Value————18,348.1
Revenue1,685.12,009.12,893.63,129.43,329.6
Growth %, YoY—+19.2+44.0+8.1—
EBITDA536.7674.81,017.21,120.11,160.8
Margin %31.8533.5935.1535.7934.86
EBIT419.7492.2701.7840.6875.4
Net Income374.2397.1374.7647.5718.4
Margin %22.2019.7612.9520.6921.58
EPS, Adj (current shares)27.5928.3025.4044.7351.09
Growth %, YoY—+2.6-10.2+76.1—
Cash from Operations291.7486.01,065.0538.0—
Capital Expenditures-841.4-129.2-155.0-296.9—
Free Cash Flow-549.7356.8910.0241.1241.1
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Eris Lifesciences financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Eris Lifesciences (NSE: ERIS) had a market capitalisation of ₹16,139 crore at the 29 October 2026 close (₹1,163.60 a share), a PE ratio of 22.8 on the last four quarters' profit and a price-to-book ratio of 3.89. In FY26 its consolidated net profit attributable to shareholders was ₹620 crore on revenue of ₹3,129 crore; in Q2 FY27 (July–September 2026) it was ₹184 crore, up 52.9% year on year. Its debt-to-equity ratio was 0.58 on 30 September 2026. Promoters held 54.74% of the shares on 30 September 2026.

Share price used
₹1,163.60 · 29 October 2026 close
Latest balance sheet
30 September 2026
Shareholding pattern
30 September 2026

Eris Lifesciences at a glance · consolidated

Market cap
₹16,139 Crat ₹1,163.60 · 29 Oct close
PE ratio (last 4 quarters)
22.826.1 on FY26 profit
Price to book (PB)
3.89book value ₹298.80 a share
ROE (FY26)
18.3%+5.4 pts vs FY25ROCE 15.4%
Debt to equity
0.58net debt ₹2,128 Cr
Promoter holding
54.74%+0.6 pts vs 30 Jun 202630 September 2026
Dividend yield
0.62%₹7.21 a share in 12 months
Net worth
₹4,144 Cr+34.1% vs 30 Sep 202530 September 2026
Free cash flow (FY26)
₹241 Cr−73.5% vs FY25

Questions

What is the Eris Lifesciences PE ratio today?

Eris Lifesciences' PE ratio is 22.8 at the 29 October 2026 close (₹1,163.60 a share): a market capitalisation of ₹16,139 crore divided by consolidated net profit attributable to shareholders of ₹708 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit attributable to shareholders (₹620 crore) it is 26.1.

What is the Eris Lifesciences net worth?

Eris Lifesciences' net worth — shareholders' equity in its consolidated balance sheet — was ₹4,144 crore on 30 September 2026, up 34.1% from ₹3,091 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹16,139 crore at the 29 October 2026 close.

What is the Eris Lifesciences book value per share?

Eris Lifesciences' book value per share was ₹298.80 on 30 September 2026: shareholders' equity of ₹4,144 crore divided by the 13.87 crore shares in issue, up 31.7% from ₹226.96 a year earlier. The share price at the 29 October 2026 close was ₹1,163.60.

What is the Eris Lifesciences PB ratio (price to book value)?

Eris Lifesciences' price-to-book (PB) ratio is 3.89 at the 29 October 2026 close: a market capitalisation of ₹16,139 crore divided by shareholders' equity (book value) of ₹4,144 crore on 30 September 2026. That is a book value of ₹298.80 per share against a share price of ₹1,163.60.

What is the Eris Lifesciences ROE and ROCE?

In FY26, Eris Lifesciences' return on equity (ROE) was 18.3% and its return on capital employed (ROCE) was 15.4%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 12.9% and ROCE 13.8%.

What is the Eris Lifesciences promoter holding?

Promoters held 54.74% of Eris Lifesciences on 30 September 2026, up 0.60 percentage points from 54.14% the previous quarter and down 0.11 percentage points from 54.85% a year earlier, according to the shareholding pattern filed with NSE.

What is the Eris Lifesciences market cap?

Eris Lifesciences' market capitalisation was ₹16,139 crore at the 29 October 2026 close: 13.87 crore shares at ₹1,163.60 each.

Is Eris Lifesciences debt free?

No. Eris Lifesciences had borrowings of ₹2,382 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.58. Its cash and current investments were ₹254 crore, so its net debt was ₹2,128 crore.

What is the Eris Lifesciences dividend in 2026 and its record date?

In 2026, Eris Lifesciences has declared one dividend: ₹7.21 (interim) with record date 29 May 2026.

What is the Eris Lifesciences debt to equity ratio?

Eris Lifesciences' debt-to-equity ratio was 0.58 on 30 September 2026: borrowings of ₹2,382 crore against total equity of ₹4,142 crore. A year earlier, on 30 September 2025, it was 0.68.

What is the Eris Lifesciences dividend yield?

Eris Lifesciences' dividend yield is 0.62% at the 29 October 2026 close: dividends of ₹7.21 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹1,163.60. They were ₹7.21 on 29 May 2026 (interim).

What is the Eris Lifesciences free cash flow?

In FY26, Eris Lifesciences generated ₹538 crore of cash from operations and spent ₹297 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹241 crore. In FY25 it was ₹910 crore.

What is the Eris Lifesciences EPS?

Eris Lifesciences' basic earnings per share (EPS) were ₹45.33 in FY26, against ₹25.85 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹51.46.

What are the Eris Lifesciences latest quarterly results?

Eris Lifesciences' latest results are for Q2 FY27 (July–September 2026), filed on 26 October 2026: consolidated net profit attributable to shareholders ₹184 crore, up 52.9% from ₹120 crore in Q2 FY26; revenue from operations ₹892 crore, up 12.6% year on year.

When are the Eris Lifesciences next results?

Eris Lifesciences has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.

What is the Eris Lifesciences shareholding pattern?

On 30 September 2026, Eris Lifesciences' shares were held by promoters 54.74%, foreign portfolio investors (FII/FPI) 5.74%, domestic institutions (DII) 20.20% (including mutual funds at 17.98%) and retail and other non-institutional investors 19.32%. Over the year, FII holding was down 1.47 percentage points from 7.21% and DII holding was up 0.84 percentage points from 19.36%.

What is the Eris Lifesciences revenue and profit in FY26?

In FY26 (April 2025–March 2026), Eris Lifesciences' consolidated net profit attributable to shareholders was ₹620 crore, up 76.1% from ₹352 crore in FY25, on revenue from operations of ₹3,129 crore (up 8.1%). Over three years, from FY23, net profit was up 62.1%.

How does the Eris Lifesciences PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, Eris Lifesciences' PE ratio is 26.1, the lowest of the four: Mankind Pharma 53.3, Ajanta Pharmaceuticals 41.1 and Torrent Pharma 80.5, a peer average of 58.3. Each is the company's market capitalisation at that price divided by its FY26 net profit.

How does Eris Lifesciences compare with its peers?

On FY26 consolidated figures, against Mankind Pharma, Ajanta Pharmaceuticals and Torrent Pharma: Eris Lifesciences' operating margin of 26.9% is the highest of the four (Mankind Pharma 19.1%, Ajanta Pharmaceuticals 22.4%, Torrent Pharma 24.6%; peer average 22.0%); its return on equity of 18.3% is the third highest of the four (Mankind Pharma 12.5%, Ajanta Pharmaceuticals 25.4%, Torrent Pharma 27.1%; peer average 21.7%); its revenue growth over three years of 22.9% a year is the highest of the four (Mankind Pharma 17.7% a year, Ajanta Pharmaceuticals 13.4% a year, Torrent Pharma 13.3% a year; peer average 14.8% a year).

Eris Lifesciences vs Mankind Pharma: how do they compare?

In FY26, Eris Lifesciences earned net profit attributable to shareholders of ₹620 crore on revenue of ₹3,129 crore, against ₹1,913 crore on ₹14,278 crore for Mankind Pharma. Eris Lifesciences' operating margin was 26.9% (Mankind Pharma 19.1%) and its return on equity 18.3% (Mankind Pharma 12.5%). At the 29 October 2026 close, Eris Lifesciences' market capitalisation was ₹16,139 crore against ₹1,01,982 crore for Mankind Pharma, and its PE ratio on FY26 profit 26.1 against 53.3.

Where do these Eris Lifesciences figures come from?

From Eris Lifesciences' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.